Universität zu Köln

Zengerling, Friedemann, Beyersdorff, Dirk, Busch, Jonas, Heinzelbecker, Julia ORCID: 0000-0001-8993-7171, Pfister, David, Ruf, Christian, Winter, Christian, Albers, Peter, Kliesch, Sabine and Schmidt, Stefanie (2022). Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review. World J. Urol., 40 (12). S. 2879 - 2888. NEW YORK: SPRINGER. ISSN 1433-8726

Full text not available from this repository.

Abstract

Objective To systematically evaluate evidence on prognostic factors for tumor recurrence in clinical stage I nonseminoma patients other than lymphovascular invasion (LVI). Methods We performed a systematic literature search in the biomedical databases Medline (via Ovid) and Cochrane Central Register of Controlled Trials (search period January 2010 to February 2021) for full text publications in English and German language, reporting on retro- or prospectively assessed prognostic factors for tumor recurrence in patients with stage I nonseminomatous germ cell tumors. Results Our literature search yielded eleven studies reporting on 20 potential prognostic factors. Results are based on cohort studies of mostly moderate to low quality. Five out of eight studies found a significant association of embryonal carcinoma (EC) in the primary tumor with relapse. Among the different risk definitions of embryonal carcinoma (presence, predominance, pure), presence of EC alone seems to be sufficient for prognostification. Interesting results were found for rete testis invasion, predominant yolk sac tumor, T-stage and history of cryptorchidism, but the sparse data situation does not justify their clinical use. Conclusions No additional factors that meet the prognostic value of LVI, especially when determined by immunohistochemistry, could be identified through our systematic search. The presence of EC might serve as a second, subordinate prognostic factor for clinical use as the data situation is less abundant than the one of LVI. Further efforts are necessary to optimize the use of these two prognostic factors and to evaluate and validate further potential factors with promising preliminary data.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zengerling, Friedemann UNSPECIFIED UNSPECIFIED UNSPECIFIED Beyersdorff, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Busch, Jonas UNSPECIFIED UNSPECIFIED UNSPECIFIED Heinzelbecker, Julia UNSPECIFIED orcid.org/0000-0001-8993-7171 UNSPECIFIED Pfister, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Ruf, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Winter, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Albers, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Kliesch, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt, Stefanie UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-692503
DOI:	10.1007/s00345-022-04063-7
Journal or Publication Title:	World J. Urol.
Volume:	40
Number:	12
Page Range:	S. 2879 - 2888
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-8726
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GERM-CELL TUMORS; LYMPH-NODE DISSECTION; RISK-FACTORS; RELAPSE; SURVEILLANCE; INDEX Multiple languages Urology & Nephrology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69250